Importantly, in EGFR-mutant/BRAF V600E NSCLC patients, the dabrafenib/trametinib/osimertinib triple combination therapy has demonstrated manageable toxic side effects (Huang et al, 2019; Meng et al, 2020; Zhou et al, 2020; Ribeiro et al, 2021; Chimbangu et al, 2024). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.